<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610805</url>
  </required_header>
  <id_info>
    <org_study_id>PRO07050181</org_study_id>
    <nct_id>NCT00610805</nct_id>
  </id_info>
  <brief_title>Cardiology Prevention in Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>Cardiology Prevention Trial in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arthritis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a feasibility study of aggressive CV risk factor management directed by preventive&#xD;
      cardiology compared to usual care. We will determine: 1) the efficacy of a preventive&#xD;
      cardiology program compared to usual care in slowing the progression of carotid IMT and&#xD;
      plaque, and 2) the effect of a preventive cardiology program versus usual care at achieving&#xD;
      CV risk factor target goals.&#xD;
&#xD;
      We hypothesize Lupus patients randomized to the preventive cardiology program will have less&#xD;
      cardiovascular progression over two years than those lupus patients who are given standard&#xD;
      care for cardiovascular risk, defined by carotid intima-media thickness and plaque.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will recruit 30 eligible patients from the Lupus Center of Excellence outpatient clinic.&#xD;
      Patients will either be randomized into a preventive cardiology program for aggressive&#xD;
      treatment, or randomized to usual care (1:1 ratio) in a single-blinded, randomized trial of&#xD;
      24 months duration. In this feasibility trial we hope to identify and refine any limitations&#xD;
      in anticipation of designing a larger, randomized intervention study.&#xD;
&#xD;
      For both arms of the study, at baseline, 6 month, 12 month, 18 month, and 24 month visits (5&#xD;
      visits in total) all patients will be seen by Dr. Elliott, Principal Investigator. Visits&#xD;
      will include an interview, fasting laboratory tests completion of questionnaires regarding&#xD;
      demographics, socioeconomic status, health status, and risk factors (traditional,&#xD;
      inflammatory, and lupus-specific). Dr. Elliott will perform the physical examinations on all&#xD;
      patients and complete the lupus-specific disease activity and damage questionnaires. At the&#xD;
      Baseline visit, 12-month visit, and 24 24-month visits, all patients will have a carotid&#xD;
      ultrasound.&#xD;
&#xD;
      Cohort 1: Preventive Cardiology Program arm: Above and beyond the standard care, which is&#xD;
      listed below, the patients in this arm will be aggressively treated by the cardiologist. As&#xD;
      deemed prudent, the following may be prescribed: antihypertensives, lipid reducing agents,&#xD;
      anti-platelets, further cardiac testing, and behavioral modifications. No standard care&#xD;
      treatment will be withheld.&#xD;
&#xD;
      Cohort 2: Standard Care arm: The PI will send a letter of all testing results to their&#xD;
      designated PCP. No standard care treatment will be withheld.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of a preventive cardiology program compared to usual care in slowing the progression of carotid IMT and plaque</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of a preventive cardiology program versus usual care at achieving CV risk factor target goals.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm (n=15) will be followed by Preventive Cardiology and will have appropriate goal oriented interventions on their risk factor levels for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants randomized to this arm (n=15) will receive usual care. The PI will send a letter of all testing results to their primary care physician. No standard care will be withheld.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preventive Cardiology</intervention_name>
    <description>Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Participants will receive usual care per their primary care physician.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Definitive diagnosis of SLE&#xD;
&#xD;
          2. &gt;18 years of age&#xD;
&#xD;
          3. Followed by rheumatologists (not the investigator, Dr. Elliott) at the Lupus Center of&#xD;
             Excellence&#xD;
&#xD;
          4. Informed consent signed&#xD;
&#xD;
          5. Effective form of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior cardiovascular disease history (MI, coronary angioplasty, coronary artery bypass&#xD;
             graft, abnormal coronary angiography, abnormal nuclear or treadmill stress test)&#xD;
&#xD;
          2. Prior evaluation by preventive cardiology&#xD;
&#xD;
          3. Active cardiac issues&#xD;
&#xD;
          4. Pregnancy, breastfeeding, or anticipating pregnancy in the next 2 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer R Elliott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lupus Center of Excellence, Magee Womens Hospital, 300 Halket St, Suite 1750</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical and Translational Research Center (CTRC), Montefiore Hospital, 6NE, 200 Lothrop St.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2008</study_first_posted>
  <last_update_submitted>January 14, 2016</last_update_submitted>
  <last_update_submitted_qc>January 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2016</last_update_posted>
  <responsible_party>
    <name_title>Jennifer Elliott, MD</name_title>
    <organization>University of Pittsburgh</organization>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>lupus</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>IMT</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

